Evaluation of Duloxetine and Innovative Pelvic Floor Muscle Training in Women With Stress Urinary Incontinence

NCT ID: NCT04140253

Last Updated: 2020-07-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

158 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-02-01

Study Completion Date

2020-03-10

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate the safety, tolerability and efficacy of duloxetine and pelvic floor muscle training in women who suffer from stress urinary incontinence

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized-intervention, parallel, multicentric study which will evaluate the safety, tolerability and efficacy of oral duloxetine and innovative pelvic floor muscle training to woman suffering from stress urinary incontinence

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stress Urinary Incontinence in Women

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Standard Duloxetine treatment

Peroral treatment with duloxetine at a dose of 40 mg twice a day

Group Type ACTIVE_COMPARATOR

Pelvic floor muscle training (PFMT) with lumbopelvic stabilization

Intervention Type BEHAVIORAL

Pelvic floor muscle training (PFMT) with lumbopelvic stabilization.

1. Educating of probands about anatomy, physiology, and pelvic floor muscles functions
2. Training of pelvic floor muscles in different position
3. Training of pelvic floor muscles with lumbopelvic stabilization

Exercise 5 times a week for 20-30 minutes a day, after initial training with a physiotherapist.

Standard Duloxetine treatment with PFMT

Peroral treatment with duloxetine at a dose of 40 mg twice a day. Pelvic floor muscle training (PFMT) with lumbopelvic stabilization.

Group Type EXPERIMENTAL

Pelvic floor muscle training (PFMT) with lumbopelvic stabilization

Intervention Type BEHAVIORAL

Pelvic floor muscle training (PFMT) with lumbopelvic stabilization.

1. Educating of probands about anatomy, physiology, and pelvic floor muscles functions
2. Training of pelvic floor muscles in different position
3. Training of pelvic floor muscles with lumbopelvic stabilization

Exercise 5 times a week for 20-30 minutes a day, after initial training with a physiotherapist.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pelvic floor muscle training (PFMT) with lumbopelvic stabilization

Pelvic floor muscle training (PFMT) with lumbopelvic stabilization.

1. Educating of probands about anatomy, physiology, and pelvic floor muscles functions
2. Training of pelvic floor muscles in different position
3. Training of pelvic floor muscles with lumbopelvic stabilization

Exercise 5 times a week for 20-30 minutes a day, after initial training with a physiotherapist.

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Woman's willing to provide written informed consent
* Women over 18 years that experience uncomplicated stress urinary incontinence
* Score of the International Consultation on Urinary Incontinence Questionnaire ≥ 14 points
* Symptoms of urinary incontinence for at least 3 consecutive months
* Have at least seven urinary incontinence episodes per week
* Degree of pelvic organ prolapse ≤ 2 stage
* Willingness to accept the randomization process and fully participate in tests

Exclusion Criteria

* Recent use of any pharmacologic agent used to treat symptoms of urinary incontinence in the past six months
* History of anti-incontinence surgery in the past 12 months
* Use of onabotulinumtoxinA for the treatment of urinary incontinence in the past 12 months
* History of pelvic prolapse repair or urethral surgery in the past 12 months
* History of pelvic floor muscle training in the past 12 months
* History of interstitial cystitis or bladder-related pain
* Chronic severe constipation
* Clinically significant renal or hepatic impairment
* Clinically significant heart impairment
* Pregnant woman, lactating, or actively trying to become pregnant
* Non-compliance with limitation of duloxetine treatment for mixed urinary incontinence
* Positive urinary tract infection
* Use of rehabilitation aids (pessary, urethral plugs, vaginal beads, etc.)
* Use of antidepressant therapy
* Insufficient understanding of pelvic floor exercises and/or omitting exercises
* Participation in any clinical study in the past six months
Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Comenius University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava

Martin, , Slovakia

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Slovakia

References

Explore related publications, articles, or registry entries linked to this study.

Hagovska M, Svihra J, Breza J Jr, Dubravicky J, Vargovcak M. A randomized, intervention parallel multicentre study to evaluate duloxetine and innovative pelvic floor muscle training in women with uncomplicated stress urinary incontinence-the DULOXING study. Int Urogynecol J. 2021 Jan;32(1):193-201. doi: 10.1007/s00192-020-04516-w. Epub 2020 Aug 27.

Reference Type DERIVED
PMID: 32852574 (View on PubMed)

Hagovska M, Svihra J. Evaluation of duloxetine and innovative pelvic floor muscle training in women with stress urinary incontinence (DULOXING): Study protocol clinical trial (SPIRIT Compliant). Medicine (Baltimore). 2020 Feb;99(6):e18834. doi: 10.1097/MD.0000000000018834.

Reference Type DERIVED
PMID: 32028393 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

24012019

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.